Our findings suggest that HDAC inhibition with agents targeting Class I HDAC enzymes induces ER stress, which ultimately results in immunogenic modulation and increased tumor sensitivity to CTL-mediated lysis (Figure 4C). The gene discussed is HDAC9; the disease is neoplasm.